LEADER 03141nam  2200613Ia 450 
001 9910791477303321
005 20230725015616.0
010   $a0-309-15727-7
010   $a1-282-78742-X
010   $a9786612787423
010   $a0-309-15130-9
035   $a(CKB)2560000000015980
035   $a(EBL)3378636
035   $a(SSID)ssj0000417279
035   $a(PQKBManifestationID)11267613
035   $a(PQKBTitleCode)TC0000417279
035   $a(PQKBWorkID)10361258
035   $a(PQKB)10448333
035   $a(MiAaPQ)EBC3378636
035   $a(Au-PeEL)EBL3378636
035   $a(CaPaEBR)ebr10405099
035   $a(CaONFJC)MIL278742
035   $a(OCoLC)923281847
035   $a(EXLCZ)992560000000015980
100   $a20100511d2010      uy             0
101 0 $aeng
135   $aurcn|||||||||
181   $ctxt
182   $cc
183   $acr
200 00$aEvaluation of biomarkers and surrogate endpoints in chronic disease$b[electronic resource] /$fCommittee on Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease, Board on Health Care Services, Board on Health Sciences Policy, Food and Nutrition Board, Institute of Medicine ; Christine M. Micheel and John R. Ball, editors
210   $aWashington, DC $cNational Academies Press$dc2010
215   $a1 online resource (335 p.)
300   $aDescription based upon print version of record.
311   $a0-309-15129-5 
320   $aIncludes bibliographical references.
327   $a""Front Matter""; ""Reviewers""; ""Preface""; ""Acknowledgments""; ""Contents""; ""Boxes, Figures, and Tables""; ""Summary""; ""1 Introduction""; ""2 Review: Evaluating and Regulating Biomarker Use""; ""3 The Biomarker Evaluation Process""; ""4 Case Studies""; ""5 Strengthening Evidence-Based Regulation""; ""Acronyms""; ""Glossary""; ""Appendix A: Table of Papers About Biomarker Qualification""; ""Appendix B: Recommendations from Related IOM Reports""; ""Appendix C: Committee Member and Consultant Biographies""; ""Appendix D: Staff Biographies""; ""Appendix E: Workshop Agenda""
327   $a""Appendix F: Speaker Biographies""
330   $a"Many people naturally assume that the claims made for foods and nutritional supplements have the same degree of scientific grounding as those for medication, but that is not always the case. The IOM recommends that the FDA adopt a consistent scientific framework for biomarker evaluation in order to achieve a rigorous and transparent process."--Publisher's description.
606   $aBiochemical markers$xEvaluation
606   $aChronic diseases
615  0$aBiochemical markers$xEvaluation.
615  0$aChronic diseases.
676   $a610.28
701   $aMicheel$b Christine$01484237
701   $aBall$b John$f1944-$01493792
712 02$aInstitute of Medicine (U.S.).$bCommittee on Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910791477303321
996   $aEvaluation of biomarkers and surrogate endpoints in chronic disease$93719241
997   $aUNINA